Comparison of the Viveve Treatment and Cryogen-Only Treatment Versus Sham Treatment for Stress Urinary Incontinence

Inclusion Criteria: * Pre-menopausal females, ≥ 18 years of age. Premenopausal is defined as a woman who has had menstrual cycles over the previous 12 months. * Subjects with a BMI of ≤ 35 kg/m². * 1-hr pad weight at Baseline with a 5 to 50 g net increase from the pre-test pad weight Exclusion Criteria: * Subjects who are currently breastfeeding or have discontinued breastfeeding fewer than 6 months prior to screening. * Subjects who are pregnant or plan to become pregnant during the course of the study. * Subjects who have undergone other stress urinary incontinence treatments, excluding behavioral modifications (e.g., Kegel exercises). * Has any implantable electrical device \[e.g., implantable pacemaker, automatic implantable cardioverter-defibrillator (AICD)\]. * Subjects who have started or changed dose of local vaginal hormones \<6 weeks before Screening. * Subjects who have started pelvic floor physical therapy within the last 3 months. * Undergone previous elective surgical or non-invasive procedure(s) in the vaginal canal (including the Viveve Treatment or any other genital radiofrequency treatment; injectable bulking agent, cosmetic, laser, surgical, and/or genital enhancement procedure, and previous dilation and cuterage within 12 months of the subject's Pre-Screening Visit).